Liminal BioSciences (LMNL) 6-K 16 Aug 21 Liminal BioSciences Reports Second Quarter 2021 Financial Results Financial data

Document and Entity Information

Document and Entity Information	6 Months Ended
	Jun. 30, 2021
Cover [Abstract]
Document Type	6-K
Amendment Flag	false
Document Period End Date	Jun. 30, 2021
Document Fiscal Year Focus	2021
Entity Registrant Name	Liminal BioSciences Inc.
Entity Central Index Key	0001351172
Current Fiscal Year End Date	--12-31

Consolidated Statements of Fina

Consolidated Statements of Financial Position (Unaudited) - CAD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Current assets
Cash	$ 29,648	$ 45,075
Accounts receivable and others	1,650	4,081
Inventories		9,377
Prepaids	6,668	14,486
Assets of disposal group held for sale (note 3)	28,270
Total current assets	66,236	73,019
Other long-term assets	285	1,353
Capital assets (note 4)	5,738	18,791
Right-of-use assets (note 5)	1,850	8,557
Intangible assets (note 6)	4,538	15,492
Deferred tax assets	572	572
Total assets	79,219	117,784
Current liabilities
Accounts payable and accrued liabilities	9,375	16,835
Current portion of lease liabilities (note 7)	4,807	6,946
Current portion of provisions (note 8)	3,078
Current portion of long-term debt (note 10)	2,600
Liabilities of disposal group held for sale (note 3)	8,095
Total current liabilities	27,955	23,781
Long-term portion of lease liabilities (note 7)	19,329	26,506
Provisions (note 8)	18,850
Warrant liability (note 9)	10,084	11,640
Long-term debt (note 10)	39,150	40,532
Other long-term liabilities	103	313
Total liabilities	115,471	102,772
EQUITY (DEFICIENCY)
Share capital (note 11a)	977,261	977,261
Contributed surplus (note 11b)	41,722	39,877
Warrants (note 11c)	95,856	95,856
Accumulated other comprehensive loss	(2,973)	(3,030)
Accumulated other comprehensive income of disposal group held for sale		184
Deficit	(1,139,354)	(1,087,049)
Equity attributable to owners of the parent	(27,488)	23,099
Non-controlling interests	(8,764)	(8,087)
Total equity (deficiency)	(36,252)	15,012
Total liabilities and equity (deficiency)	$ 79,219	$ 117,784

Consolidated Statements of Oper

Consolidated Statements of Operations (Unaudited) - CAD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Income Statement [Abstract]
Revenues	$ 25	$ 36	$ 235	$ 238
Expenses
Research and development expenses	3,951	3,981	8,835	7,996
Administration expenses	8,551	8,503	16,688	17,580
Impairment (note 6)	341		341
Loss (gain) on foreign exchange	(480)	566	(307)	(592)
Finance costs	1,661	287	2,833	524
Change in fair value of financial instruments measured at fair value through profit or loss (note 9)	(1,402)		(1,556)
Loss from continuing operations before income taxes	(12,597)	(13,301)	(26,599)	(25,270)
Current income taxes		(144)		(144)
Net loss from continuing operations	(12,597)	(13,157)	(26,599)	(25,126)
Loss from discontinued operations
Gain on sale of subsidiaries, net of income taxes $nil (note 3)	10,698		10,698
Loss from discontinued operations, net of income taxes (note 3)	(30,234)	(14,659)	(37,081)	(30,347)
Net loss	(32,133)	(27,816)	(52,982)	(55,473)
Net loss attributable to:
Non-controlling interests - continuing operations	(93)	(56)	(677)	(369)
Owners of the parent
- Continuing operations	(12,504)	(13,101)	(25,922)	(24,757)
- Discontinued operations	(19,536)	(14,659)	(26,383)	(30,347)
Total Net loss attributable to owners of the parent from continuing and discontinued operations	(32,040)	(27,760)	(52,305)	(55,104)
Net loss	$ (32,133)	$ (27,816)	$ (52,982)	$ (55,473)
Attributable to the owners of the parent basic and diluted:
From continuing operations	$ (0.42)	$ (0.56)	$ (0.87)	$ (1.06)
From discontinued operations	(0.65)	(0.63)	(0.88)	(1.29)
Total loss per share	$ (1.07)	$ (1.19)	$ (1.75)	$ (2.35)
Weighted average number of outstanding shares (in thousands)	29,944	23,420	29,944	23,403

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Loss (Unaudited) - CAD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Statement Of Comprehensive Income [Abstract]
Net Loss	$ (32,133)	$ (27,816)	$ (52,982)	$ (55,473)
Items that may be subsequently reclassified to profit and loss:
Exchange differences on translation of foreign operations from continuing operations	35	25	57	(51)
Exchange differences on translation of foreign operations from discontinued operations	(104)	(37)	(140)	119
Reclassification of exchange differences on translation of foreign operations sold to consolidated statement of operations (note 3)	(44)		(44)
Total other comprehensive income (loss)	(113)	(12)	(127)	68
Total comprehensive loss	(32,246)	(27,828)	(53,109)	(55,405)
Total comprehensive loss attributable to:
Non-controlling interests	(93)	(56)	(677)	(369)
Owners of the parent- Continuing operations	(12,469)	(13,076)	(25,865)	(24,808)
Owners of the parent- Discontinued operations	(19,684)	(14,696)	(26,567)	(30,228)
Total comprehensive loss	$ (32,246)	$ (27,828)	$ (53,109)	$ (55,405)

Consolidated Statements of Chan

Consolidated Statements of Changes in Equity (Unaudited) - CAD ($) $ in Thousands	Total	Share Capital	Contributed Surplus	Warrants	Foreign Currency Translation Reserve	Deficit	Total Equity (Deficiency) Attributable to Owners of the Parent	Non-controlling Interests
Beginning balance at Dec. 31, 2019	$ 94,934	$ 932,951	$ 43,532	$ 95,856	$ (3,099)	$ (967,051)	$ 102,189	$ (7,255)
Net Loss	(55,473)					(55,104)	(55,104)	(369)
Foreign currency translation reserve	68				68		68
Issuance of shares (note 11a)	1,240	1,240					1,240
Share-based payments expense (note 11b)	4,801		4,801				4,801
Share-based compensation paid in cash (note 11b)	(40)		(40)				(40)
Shares issued pursuant to restricted share unit plan (note 11b)		9,764	(9,764)
Share issuance cost	(8)					(8)	(8)
Ending balance at Jun. 30, 2020	45,522	943,955	38,529	95,856	(3,031)	(1,022,163)	53,146	(7,624)
Beginning balance at Dec. 31, 2020	15,012	977,261	39,877	95,856	(2,846)	(1,087,049)	23,099	(8,087)
Net Loss	(52,982)					(52,305)	(52,305)	(677)
Foreign currency translation reserve	(83)				(83)		(83)
Reclassification of exchange differences on translation offoreign operations to consolidated statement ofoperations (note 3)	(44)				(44)		(44)
Share-based payments expense (note 11b)	1,866		1,866				1,866
Share-based compensation paid in cash (note 11b)	(21)		(21)				(21)
Ending balance at Jun. 30, 2021	$ (36,252)	$ 977,261	$ 41,722	$ 95,856	$ (2,973)	$ (1,139,354)	$ (27,488)	$ (8,764)

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (Unaudited) - CAD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Cash flows used in operating activities
Net loss from continuing operations during the period	$ (26,599)	$ (25,126)
Net loss from discontinued operations during the period	(26,383)	(30,347)
Adjustments to reconcile net loss to cash flows used in operating activities:
Finance costs and foreign exchange	6,129	2,805
Loss from disposition of capital and intangible assets	(335)	83
Gain on sale of subsidiaries (note 3)	(10,698)
Change in fair value of financial instruments measured at fair value through profit or loss (note 9)	(1,556)
Impairment losses (note 6)	341
Gain on extinguishments of liabilities		(79)
Provision expense (note 8)	21,928
Share-based payments expense (note 11b)	1,845	4,761
Depreciation of capital assets (note 4)	1,121	1,314
Depreciation of right-of-use assets (note 5)	736	2,264
Amortization of intangible assets (note 6)	922	494
Cash flows from (used in) operations before changes in working capital	(32,549)	(43,831)
Change in non-cash working capital items	2,902	11,894
Cash flows used in operating activities	(29,647)	(31,937)
Cash flows used in financing activities
Repayment of principal on long-term debt		(165)
Repayment of interest on long-term debt (note 10)	(973)	(503)
Payments of principal on lease liabilities (note 7)	(3,752)	(3,066)
Payment of interest on lease liabilities (note 7)	(1,251)	(853)
Debt, share and warrants issuance costs	(158)	(8)
Cash flows from financing activities	(6,134)	(4,595)
Cash flows from (used in) investing activities
Additions to capital assets	(208)	(370)
Additions to intangible assets	(118)	(499)
Proceeds from sale of discontinued operations business	21,400	1,175
Transaction costs paid relating to the sale of discontinued operations business	(265)	(787)
Proceeds from disposal of capital assets	49
Release of restricted cash	161
Interest received	39	283
Cash flows used in investing activities	21,058	(198)
Net change in cash and cash equivalents during the period	(14,723)	(36,730)
Net effect of currency exchange rate on cash and cash equivalents	(704)	1,431
Cash and cash equivalents, beginning of period	45,075	61,285
Cash and cash equivalents, end of period	29,648	25,986
Comprising of:
Cash	$ 29,648	21,806
Cash equivalents		$ 4,180

Nature of operations and going

Nature of operations and going concern	6 Months Ended
	Jun. 30, 2021
Disclosure Of Nature Of Operations And Going Concern [Abstract]
Nature of operations and going concern	1. Nature of operations and going concern Liminal BioSciences Inc. (“Liminal” or “the Company”) is incorporated under the Canada Business Corporations Act and is a publicly traded clinical-stage biotechnology company (Nasdaq symbol: LMNL) focused on discovering, developing and commercializing novel treatments for patients suffering from diseases of unmet medical need, primarily related to fibrosis, including respiratory, liver and kidney diseases. The Company’s lead product candidate, fezagepras is in the clinical development stage and its GPR84 antagonist and OXER1 antagonist R&D programs are currently both at the pre-clinical research stage. The Company previously operated a segment devoted to the development of plasma-derived therapeutics, leveraging Liminal’s experience in bioseparation technologies used to isolate and purify biopharmaceuticals from human plasma and received approval, from the U.S. Food and Drug Administration or FDA in June 2021 for its plasma-derived product Ryplazim ® ® The Company’s registered office is located at 440, Boul. Armand-Frappier, suite 300, Laval, Québec, Canada, H7V 4B4. Liminal has Research and Development facilities in Canada and the U.K., and manufacturing facilities in Canada. Structured Alpha LP or SALP has been Liminal’s majority and controlling shareholder since the debt restructuring on April 23, 2019 and is considered Liminal’s parent entity for accounting purposes. Thomvest Asset Management Ltd. is the general partner of SALP and the ultimate controlling parent, for accounting purposes, of Liminal is The 2003 TIL Settlement. Prior to this date, Liminal did not have a controlling parent. The interim financial statements are presented in Canadian dollars, $ or CA$, and have been prepared in accordance with International Financial Reporting Standards, or IFRS, as issued by the International Accounting Standards Board, or IASB, on a going concern basis, which presumes the Company will continue its operations for the foreseeable future and will be able to realize its assets and discharge its liabilities and commitments in the ordinary course of business. During the six months ended June 30, 2021, the Company incurred a net loss of $53.0 million ($55.5 million for the six months ended June 30, 2020) and had negative operating cash flows of $29.6 million ($31.9 million for the six months ended June 30, 2020). In addition at June 30, 2021, the Company had a working capital of $38.3 million ($49.2 million at December 31, 2020) and an accumulated deficit of $1,139.4 million ($1,087.0 million at December 31, 2020). After the June 30, 2021 quarter end, the Company’s subsidiary, Prometic Biotherapeutics Inc., or PBT, entered into a definitive agreement on August 6, 2021 for the sale of the Priority Review Voucher, or PRV, it received on June 4, 2021 in conjunction with the FDA approval of its Biologics License Application for Ryplazim ® The closing is subject to customary closing conditions, including all applicable U.S. antitrust clearance requirements. The Company continues operating at lower spending levels than historically, pacing investments on new research programs, and reducing infrastructure cost, where possible. Until the Company closes the sale of the PRV, completes a significant financing, or it can generate sufficient revenues to finance its future cash requirements, it may likely need to secure additional external financing which may include public or private equity offerings, debt financings, strategic collaborations, alliances and licensing arrangements, grant funding or other sources. On August 6, 2021, the Company’s subsidiary, Prometic Biotherapeutics Inc., or PBT, entered into a definitive agreement to for the sale of the Priority Review Voucher, or PRV, it received on June 4, 2021 in conjunction with the FDA approval of it Biologics License Application for Ryplazim ® Despite the Company’s efforts to obtain the necessary funding and improve profitability of its operations, there can be no assurance of its success in doing so, especially with respect to its access to further funding on acceptable terms, if at all. These circumstances indicate the existence of a material uncertainty that may cast substantial doubt about the Company’s ability to continue as a going concern. If the Company is unable to secure additional capital or monetize the PRV, it may be required to curtail its research and development initiatives and take additional measures to reduce costs in order to conserve its cash in amounts sufficient to sustain operations and meet its obligations. These measures could cause significant delays in the Company’s preclinical, clinical and regulatory efforts, which are critical to the realization of its business plan. These interim financial statements do not include any adjustments to the amounts and classification of assets and liabilities that might be necessary should the Company be unable to continue as a going concern. Such adjustments could be material.

Significant accounting policies

Significant accounting policies	6 Months Ended
	Jun. 30, 2021
Significant Accounting Policies [Abstract]
Significant accounting policies	2. Significant accounting policies a) Accounting framework These interim financial statements have been prepared in accordance with IAS 34, Interim financial reporting These interim financial statements were approved for issue on August 15, 2021 by the Company’s Audit, Risk and Finance committee as delegated by the Board of Directors. b) New standards and interpretations adopted The accounting policies used in these interim financial statements are consistent with those applied by the Company in its December 31, 2020 audited annual consolidated financial statements except for the adoption of the following amendment on January 1, 2021. Amendment to IFRS 16 Leases or - IFRS 16 has been revised to incorporate an amendment issued by the IASB in May 2020. The amendment permits lessees not to assess whether particular COVID-19-related rent concessions are lease modifications and, instead, account for those rent concessions as if they were not lease modifications. In addition, the amendment to IFRS 16 provides specific disclosure requirements regarding COVID-19-related rent concessions. The adoption of this amendment had no impact on the interim financial statements since the Company has not benefited from COVID-19 related rent concessions. c) New standards and interpretations not yet adopted The IFRS accounting standards, amendments, and interpretations that the Company reasonably expects may have a material impact on the disclosures, the financial position or results of operations of the Company when applied at a future date are as follows: Amendments to IAS 1, Presentation of Financial Statements (IAS 1) and IAS 8, Accounting policies, Changes in Accounting Estimates and Errors (IAS 8) The amendments to IAS 1 require entities to disclose their material accounting policies rather than their significant accounting policies and provides guidance to apply materiality judgments to accounting policy disclosure. The amendments to IAS 8 introduce a definition of accounting estimates and provide clarifications to distinguish accounting policies from accounting estimates. The amendments are effective for annual reporting periods beginning on or after January 1, 2023 with earlier application permitted. The Company is evaluating the impact of these changes on its financial statements. d ) Significant accounting judgements and critical accounting estimates The preparation of the interim consolidated financial statements requires the use of judgments, estimates and assumptions that affect the reported amounts of revenues, expenses, assets and liabilities and the accompanying disclosures. The uncertainty that is often inherent in these estimates and assumptions could result in material adjustments to assets or liabilities affected in future periods. The significant accounting judgments and critical accounting estimates applied by the Company, disclosed in the audited annual consolidated financial statements for the year ended December 31, 2020, remain unchanged.

Assets and Liabilities Held for

Assets and Liabilities Held for Sale and Discontinued Operations	6 Months Ended
	Jun. 30, 2021
Disclosure Of Assets And Liabilities Held For Sale And Discontinued Operations [Abstract]
Assets and Liabilities Held for Sale and Discontinued Operations	3. Assets and liabilities held for sale and discontinued operations The Company entered into two share purchase agreements or SPA(s), with Kedrion; the first for the sale of its plasma collection centers operated by Prometic Plasma Resources Inc. and Prometic Plasma Resources USA Inc., and the second for the sale of its Ryplazim ® ® The sale of the plasma collection centers was closed on May 21, 2021. Concurrently with the closing of this transaction, the Company entered into an option agreement or Option which granted to Kedrion the right to acquire the Ryplazim business by June 15, 2021 which was subsequently extended to June 22, 2021. The SPA for the Ryplazim ® ® As a result of the signing of the SPA for the Ryplazim ® The major classes of assets, liabilities and accumulated other comprehensive income pertaining to the disposal group and classified as held for sale are as follows: Accounts receivable $ 1,503 Inventories 4,571 Prepaids 322 Other long-term assets 50 Capital assets 9,303 Intangible assets 8,657 Right-of-use assets 3,864 Total assets of disposal group held for sale 28,270 Accounts payable and accrued liabilities 3,151 Current portion of lease liabilities 989 Long-term portion of lease liabilities 3,955 Total liabilities of disposal group held for sale 8,095 Discontinued operations During the quarter ended March 31, 2021, the Company had determined that the plasma collection activities met the criteria to be presented as discontinued operations for the current quarter and comparative periods. Results of operations and other comprehensive loss of that disposal group had been presented as discontinued operations. Following the signing of the SPA for the Ryplazim ® Since the Company’s continuing operations all pertain to the small molecule segment, Liminal will no longer be presenting segmented information. Previously, on November 25, 2019, the Company sold two subsidiaries in its bioseparations segment, representing the majority of its bioseparations operations and all of the bioseparations revenues. The results of the comparative periods of the business sold have also been presented as discontinued operations, however for the quarter and six months ended June 30, 2020, the results of this discontinued operation were $nil. The consolidated statement of cash flows were not restated to present the cash flows from the discontinued operations separately as the Company selected to provide this information in the present note. Results and cash flows from discontinued operations The net loss from the discontinued operations for the quarters and six months ended June 30, 2021 and 2020 are follows: Quarter ended June 30, Six months ended June 30, 2021 2020 2021 2020 Plasma-derived therapeutics segment: Revenues $ 423 $ 504 $ 949 $ 1,405 Expenses Cost of sales and other production expenses 750 468 1,456 1,104 Research and development expenses 1) 27,992 11,806 32,355 24,824 Administration expenses 1,095 1,348 2,190 2,943 Gain on foreign exchange (4 ) (27 ) (138 ) (1 ) Finance costs 823 1,565 2,166 2,958 Gain on extinguishment of liabilities — — — (79 ) Current income taxes 1 3 1 3 Loss from discontinued operations, net of income taxes $ (30,234 ) $ (14,659 ) $ (37,081 ) $ (30,347 ) 1) The cost of an onerous contract (note 8) is included in research and development expenses for the quarter and six months ended June 30, 2021. The cash flows from discontinued operations for the quarters and six months ended June 30, 2021 and 2020 are as follows: June 30, 2021 June 30, 2020 Bioseparations activities Cash flows from investing activities $ — $ 388 Cash generated during the period $ — $ 388 Plasma-derived therapeutic activities Cash flows from in operating activities 1) $ 4,734 $ 5,265 Cash flows used in financing activities (3,469 ) (3,192 ) Cash flows from (used) in investing activities 20,250 (222 ) Net effect of currency exchange rate on cash (31 ) 89 Cash flows generated during the period $ 21,484 $ 1,940 Total cash flows generated from discontinued operations $ 21,484 $ 2,328 1) Gain on sale of subsidiaries The details of the gain on sale of subsidiaries during the quarter ended June 30, 2021 is provided in the table below. Sale of plasma collection entities Fair value of the consideration received and receivable $ 12,826 Less: Carrying amount of net assets sold 10,849 Transaction costs 204 Reclassification of foreign currency translation reserve from other comprehensive income into the statement of operations (44 ) Gain on sale of plasma collection entities 1,817 Sale of Ryplazim entities Fair value of proceeds received or receivable at June 30, 2021 9,084 Less: Transaction costs 203 Gain on sale of Ryplazim entities recognized at June 30, 2021 8,881 Gain on sale of subsidiaries, net of income taxes $nil $ 10,698 The carrying amounts of the assets and liabilities sold as part of the sale of the plasma collection centers are as follows: Accounts receivable $ 137 Inventories 8,441 Prepaids 21 Other long-term assets 54 Capital assets 2,376 Right-of-use assets 2,000 Intangible assets 1,092 Total assets $ 14,121 Accounts payable and accrued liabilities 639 Deferred revenue - Current portion of lease liabilities 665 Long-term portion of lease liabilities 1,968 Total liabilities $ 3,272 Net assets sold $ 10,849 In addition to the details above, on July 9, 2021, the Company received US$9.1 million at the closing of the sale of PBP. The PBT sale transaction is not closed as of the date of these interim financial statements. As part of the SPA covering this upcoming transaction, the Company is to receive proceeds of approximately US$5.2 million subject to an adjustment for working capital. Also, prior to the close of the transaction, PBT will need to pay PBP, which is now owned by Kedrion, an amount equivalent to 30% of the net proceeds it receives from the sale of the PRV in compensation for past services.

Capital assets

Capital assets	6 Months Ended
	Jun. 30, 2021
Disclosure Of Property Plant And Equipment [Abstract]
Capital assets	4 . Capital assets Production Furniture and Land and Leasehold and laboratory computer Buildings improvements equipment equipment Total Cost Balance at January 1, 2021 $ 4,567 $ 7,349 $ 29,904 $ 3,365 $ 45,185 Additions — — 60 4 64 Disposals — (399 ) (1,420 ) (301 ) (2,120 ) Sold - discontinued operations (note 3) — (1,921 ) (973 ) (212 ) (3,106 ) Effect of foreign exchange differences — (107 ) (45 ) (9 ) (161 ) Reclassified to assets held for sale (note 3) — (4,403 ) (20,552 ) (1,875 ) (26,830 ) Balance at June 30, 2021 $ 4,567 $ 519 $ 6,974 $ 972 $ 13,032 Accumulated depreciation Balance at January 1, 2021 $ 804 $ 2,901 $ 20,208 $ 2,481 $ 26,394 Depreciation expense 96 242 586 197 1,121 Disposals — (400 ) (1,236 ) (303 ) (1,939 ) Sold - discontinued operations (note 3) — (273 ) (335 ) (122 ) (730 ) Effect of foreign exchange differences — (12 ) (8 ) (5 ) (25 ) Reclassified to assets held for sale (note 3) — (2,121 ) (13,923 ) (1,483 ) (17,527 ) Balance at June 30, 2021 $ 900 $ 337 $ 5,292 $ 765 $ 7,294 Carrying amounts At June 30, 2021 $ 3,667 $ 182 $ 1,682 $ 207 $ 5,738 At December 31, 2020 3,763 4,448 9,696 884 18,791

Right-of-use assets

Right-of-use assets	6 Months Ended
	Jun. 30, 2021
Disclosure Of Quantitative Information About Rightofuse Assets [Abstract]
Right-of-use assets	5 . Right-of-use assets Production and laboratory Buildings equipment Other Total Net book value as at January 1, 2021 $ 8,086 $ 426 $ 45 $ 8,557 Lease modifications and other remeasurements (8 ) 1 (11 ) (18 ) Sold - discontinued operations (note 3) (1,717 ) (272 ) (11 ) (2,000 ) Depreciation expense (642 ) (83 ) (11 ) (736 ) Effect of foreign exchange differences (78 ) (6 ) (5 ) (89 ) Reclassified to assets held for sale (note 3) (3,791 ) (66 ) (7 ) (3,864 ) Net book value at June 30, 2021 $ 1,850 $ — $ — $ 1,850

Intangible assets

Intangible assets	6 Months Ended
	Jun. 30, 2021
Disclosure Of Intangible Assets [Abstract]
Intangible assets	6. Licenses and other rights Patents Software Total Cost Balance at January 1, 2021 $ 162,064 $ 6,783 $ 3,306 $ 172,153 Additions — 93 (1 ) 92 Disposals — (12 ) — (12 ) Sold - discontinued operations (note 3) (1,268 ) — (345 ) (1,613 ) Effect of foreign exchange differences 1 (19 ) (19 ) (37 ) Reclassified to assets held for sale (note 3) (13,739 ) (1,393 ) (2,122 ) (17,254 ) Balance at June 30, 2021 $ 147,058 $ 5,452 $ 819 $ 153,329 Accumulated amortization Balance at January 1, 2021 $ 150,528 $ 4,429 $ 1,704 $ 156,661 Amortization expense 109 534 279 922 Disposals — (3 ) (1 ) (4 ) Sold - discontinued operations (note 3) (433 ) — (88 ) (521 ) Impairments — 341 — 341 Effect of foreign exchange differences 18 (22 ) (7 ) (11 ) Reclassified to assets held for sale (note 3) (6,861 ) (507 ) (1,229 ) (8,597 ) Balance at June 30, 2021 $ 143,361 $ 4,772 $ 658 $ 148,791 Carrying amounts At June 30, 2021 $ 3,697 $ 680 $ 161 $ 4,538 At December 31, 2020 11,536 2,354 1,602 15,492 During the quarter ended June 30, 2021, the Company decided it would not be moving

Lease liabilities

Lease liabilities	6 Months Ended
	Jun. 30, 2021
Lease Liabilities [Abstract]
Lease liabilities	7 . Lease liabilities Balance at January 1, 2021 $ 33,452 Additions — Interest expense 2,636 Payments (5,003 ) Derecognized - discontinued operations (note 3) (2,633 ) Lease modification and other remeasurements 1,058 Effect of foreign exchange differences (430 ) Reclassified to liabilities held for sale (4,944 ) Balance at June 30 $ 24,136 Less current portion of lease liabilities 4,807 Long-term portion of lease liabilities $ 19,329 Interest expense on lease liabilities for the quarter and six months ended June 30, 2021 was $1,283 and $2,636 ($1,604 and $3,153 for the quarter and six months ended June 30, 2020) and is included as part of finance costs in the consolidated statement of operations.

Provisions

Provisions	6 Months Ended
	Jun. 30, 2021
Restructuring Provision [Abstract]
Provisions	8 . Provisions The Company has ® Provision recognized during the period $ 21,928 Less current portion of provisions 3,078 Long-term portion of provisions $ 18,850

Warrant liability

Warrant liability	6 Months Ended
	Jun. 30, 2021
Warrant Liability [Abstract]
Warrant liability	9. Warrant liability As part of the consideration for the private placement completed on November 3, 2020 where SALP and another investor participated equally, and a subsequent amendment to this private placement agreement on November 25, 2020, the Company issued a total of 7,894,734 warrants that expire on November 3, 2025. Both of these issuances combined are referred to as the November 2020 warrants. Each warrant can be exercised to acquire one common share at an exercise price initially set at US$5.50 and that can be reduced if equity financings are completed at a lower price before its expiry. The November 2020 warrants do not meet the definition of an equity instrument since the exercise price is denominated in US$ which is different than the functional currency of Liminal which is the CA$. Consequently, they are accounted for as a financial instrument, presented as a warrant liability in the consolidated statement of financial position and carried at fair value through profit or loss. The fair value of the November 2020 warrants was $10,084 and $11,640 at June 30, 2021 and December 31, 2020 respectively. The fair value for the November 2020 warrants held by SALP was $5,042 and $5,820 on those same dates. A gain of $1,402 and $1,556, resulting from the change in fair value of the November 2020 warrants during the quarter ended June 30, 2021 and the 6 months ended June 30, 2021, respectively was recognized in the consolidated statement of operations. The fair value of the November 2020 warrants on the various dates discussed above was calculated using a Black-Scholes option pricing model in a Monte Carlo simulation in order to evaluate the downward adjustment mechanism to the exercise price. The assumptions used at the different valuation dates are provided in the table below: June 30, December 31, 2021 2020 Underlying common share fair value (in US$) $ 3.89 $ 4.20 Remaining life until expiry 4.3 4.8 Volatility 51.0 % 49.0 % Risk-free interest rate 0.75 % 0.34 % Expected dividend rate — — Fair value of a warrant calculated using a Black-Sholes pricing model (in US$) $ 1.22 $ 1.41 Fair value of exercise price adjustment mechanism (in US$) $ 0.21 $ 0.22 Illiquidity discount 28.0 % 29.0 % Fair value of a warrant (in US$) $ 1.03 $ 1.16 Fair value of a warrant (in CA$) $ 1.28 $ 1.47

Long-term debt

Long-term debt	6 Months Ended
	Jun. 30, 2021
Disclosure Of Detailed Information About Borrowings [Abstract]
Long-term debt	10. Long-term debt Balance at January 1, 2021 $ 40,532 Stated and accreted interest 2,191 Repayment of stated interest (973 ) Balance at June 30, 2021 $ 41,750 At June 30, 2021, the carrying amount of the debt comprised the following loans: First term loan having a principal of $10,000 maturing on April 23, 2024 bearing stated interest of 8% per annum (effective interest rate of 15.05%) 1) $ 9,295 Second term loan having a principal of $29,123 maturing on April 23, 2024 bearing stated interest of 10% per annum (effective interest rate of 10.47%) 1) 29,855 Secured convertible debentures having an aggregate principal amount of $2,410 maturing on March 31, 2022 bearing stated interest of 8% per annum (effective interest rate of 8.24%) 2) 2,600 $ 41,750 Less current portion of long-term debt (2,600 ) Long-term portion of long-term debt $ 39,150 1) 2) The secured convertible debentures are secured by all the assets of Fairhaven. The Company’s security interest created pursuant to its consolidated loan agreement with SALP, its parent, is subordinated to the security interest on the Fairhaven assets. At June 30, 2021, the Company was in compliance with all of its covenants under its long-term debt agreements.

Share capital and other equity

Share capital and other equity instruments	6 Months Ended
	Jun. 30, 2021
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Abstract]
Share capital and other equity instruments	11. Share capital and other equity instruments a) Share capital Changes in the issued and outstanding common shares of the Company during the quarters ended June 30, 2021 and 2020 were as follows: June 30, 2021 June 30, 2020 Number Amount Number Amount Balance - beginning of period 29,943,839 $ 977,261 23,313,164 $ 932,951 Issued to acquire assets — — 96,833 1,240 Shares issued pursuant to a restricted share units plan (note 11b) — — 10,355 9,764 Balance - end of period 29,943,839 $ 977,261 23,420,352 $ 943,955 On January 29, 2020, the Company issued 96,833 common shares as a consideration for the final payment for the licence acquired on January 29, 2018. This transaction was accounted for as an extinguishment of the license acquisition payment obligation and the difference between the carrying value of the liability of $1,319 and the amount recorded for the shares issued of $1,240, which were valued at the market price of the shares on their date of issuance, was recorded as a gain on extinguishment of liabilities of $79 during the quarter ended March 31, 2020. b) Contributed surplus (Share-based payments) Stock options For stock options having a CA$ exercise price, the changes in the number of stock options outstanding during the quarters ended June 30, 2021 and 2020 were as follows: June 30, 2021 June 30, 2020 Weighted Weighted average average exercise price exercise price Number (in CA$) Number (in CA$) Balance - beginning of period 2,485,555 $ 18.70 2,209,864 $ 38.72 Granted — — 436,570 14.06 Forfeited (850,274 ) 15.11 (64,141 ) 24.42 Expired — — (1,435 ) 2,433.20 Repriced - options before repricing — — (1,929,685 ) 35.14 Repriced - options after repricing — — 1,929,685 15.21 Balance - end of period 1,635,281 $ 20.56 2,580,858 $ 18.67 For stock options having a US$ exercise price, the changes in the number of stock options outstanding during the quarter ended June 30, 2021 were as follows: June 30, 2021 Weighted average exercise price Number (in US$) Balance - beginning of period 305,000 $ 4.70 Granted 90,000 4.65 Balance - end of period 395,000 $ 4.69 2021 In January 2021, 40,000 stock options having an exercise price of US$5.34, of which 20,000 stock options vested immediately and the remaining stock options vest over a period up to one year, were issued to a member of the Board of Directors. In June 2021, 50,000 stock options having an exercise price of US$4.09, of which 25,000 stock options vested immediately and the remaining stock options vest over a period up to one year, were issued to a member of the Board of Directors. The Company uses the Black-Scholes option pricing model to calculate the fair value of stock options at the date of grant. The weighted average inputs into the model and the resulting grant date fair values during the six months ended June 30, 2021 were as follows: Expected dividend rate — Expected volatility of share price 115.5 % Risk-free interest rate 0.99 % Expected life in years 6.5 Weighted average grant date fair value $ 5.00 2020 In March 2020, Liminal’s Board of Directors approved a plan to reduce the exercise price of the stock options originally issued in June 2019, which were held by active employees and directors at the time of the repricing. On May 26, 2020, a revised exercise price, pending approval, of $15.21 was determined, changing the exercise price to the higher of (i) $15.21 and (ii) the five trading-day VWAP of Liminal common shares on the repricing date. On June 8, 2020, the repricing of 1,929,685 of the outstanding stock options having exercise prices of $27.00 and $36.00 to the revised exercise price was approved at the Company’s annual shareholder meeting. Although the stock options were not repriced until May 26, 2020, management concluded that the service period for employees and directors to earn the modified awards had commenced from the date the Company informed the holders of these stock options of the repricing proposal and the expense resulting from the repricing plan should be recognized starting from that date. Using the revised exercise price of $15.21, the Company calculated the final incremental fair value of the repricing on the grant date of May 26, 2020 to be $3,000. This incremental fair-value will be amortized from the services commencement date of March 25 over the remaining vesting period of the repriced options. The incremental grant date fair value of the repriced options was estimated based on the Black-Scholes option-pricing model calculated before and after the effect of the repricing. The following Black-Scholes assumption were used: Expected dividend rate — Expected volatility of share price 93.2 % Risk-free interest rate 0.4 % Expected life in years 6.3 Weighted average grant date incremental fair value $ 1.55 At June 30, 2021, stock options issued and outstanding denominated in CA$ and US$ by range of exercise price are as follows: Weighted average Weighted Weighted Range of exercise remaining average average price for stock option Number contractual life exercise price Number exercise price issued in CA$ outstanding (in years) (CA$) exercisable (CA$) $7.86 - $11.99 171,250 8.3 $ 9.58 68,672 $ 9.73 $ 14.06 323,926 8.9 14.06 112,972 14.06 $ 15.21 1,083,328 7.9 15.21 580,241 15.21 $27.00 - $3,170.00 56,777 7.6 192.87 56,303 189.91 1,635,281 8.2 $ 20.56 818,188 $ 26.61 Weighted average Weighted Weighted Range of exercise remaining average average price for stock option Number contractual life exercise price Number exercise price issued in US$ outstanding (in years) (US$) exercisable (US$) $4.09 - $5.34 375,000 9.5 $ 4.36 165,000 $ 4.37 $ 10.80 20,000 9.3 10.80 3,333 10.80 395,000 9.5 $ 4.69 168,333 $ 4.50 A share-based payment compensation expense of $957 and $1,866 was recorded for the stock options for the quarter and six months ended June 30, 2021 respectively ($2,407 and $4,770 for the quarter and six months ended June 30, 2020). Restricted share units Changes in the number of restricted share units or RSU outstanding during the six months ended June 30, 2021 and 2020 were as follows: June 30, June 30, 2021 2020 Balance - beginning of period 4,216 17,565 Forfeited (4,048 ) (24 ) Released — (10,355 ) Paid in cash (144 ) (2,948 ) Balance - end of period 24 4,238 There was no share-based payment compensation expense recorded during the quarter and six months ended June 30, 2021. During the first quarter of 2020, 2,948 RSU were paid in cash resulting in a reduction to contributed surplus of $40. At June 30, 2021, all outstanding RSU were vested. A share-based payment compensation expense of $17 and $31 was recorded during the quarter and the six months ended June 30, 2020. Share-based payments expense The total share-based payments expense, comprising the above-mentioned expenses for stock options and RSU, has been included in the consolidated statements of operations for the quarter and six months ended June 30, 2021 and 2020 as indicated in the following table: Quarter ended June 30, Six months ended June 30, 2021 2020 2021 2020 Research and development expenses $ 467 $ 904 $ 437 $ 1,920 Administration, selling and marketing expenses 899 1,340 1,873 2,696 Loss from discontinued operations (409 ) 180 (444 ) 185 $ 957 $ 2,424 $ 1,866 $ 4,801 c) Warrants There were no changes in the number of warrants having a CA$ exercise price during the six months ended June 30, 2021 and 2020. At June 30, 2021 and 2020, the number of warrants outstanding by exercise price were as follows: June 30, 2021 June 30, 2020 Weighted Weighted average average exercise price exercise price Number (CA$) Number (CA$) Balance of warrants - end of period 172,735 $ 84.33 172,735 $ 84.33 There were no changes in the number of warrants having a US$ exercise price during the six months ended June 30, 2021. These are the same warrants presented as a warrant liability (note 9) and they are listed here with the warrants classified as equity instruments, simply so the readers may see all the warrants outstanding together. There were no warrants having a US$ exercise price issued during the six months ended June 30, 2020. June 30, 2021 Weighted average exercise price Number (US$) Balance of warrants - end of period 7,894,734 $ 5.50 At June 30, 2021, the weighted average exercise prices (in CA$ or in US$) and expiry dates for the warrants outstanding are as follows: Number Expiry date Exercise price (CA$) 4,000 January 2023 3,000.00 168,735 April 2027 15.21 Warrants outstanding with an exercise price in CA$ 172,735 $ 84.33 Number Expiry date Exercise price (US$) Warrants outstanding with an exercise price in US$ 7,894,734 November 2025 $ 5.50

Government Grants

Government Grants	6 Months Ended
	Jun. 30, 2021
Disclosure Of Government Grants [Abstract]
Government Grants	12. Government grants The Company recognized government grants in connection with the Canada Emergency Wage and Rent Subsidy programs from the second quarter of 2020, the commencement of the programs, until it ceased to be eligible to the programs during the second quarter of 2021, following the sale of its plasma collection centers (note 3). These government grants were recorded as a reduction of salary and rent expenses and are recognized as follows in the consolidated statement of operations: Quarter ended June 30, Six months ended June 30, 2021 2020 2021 2020 Research and development expenses $ 149 $ 460 $ 512 $ 460 Administration expenses 115 584 411 584 Loss from discontinued operations 940 1,901 3,182 1,901 $ 1,204 $ 2,945 $ 4,105 $ 2,945

Related party transactions

Related party transactions	6 Months Ended
	Jun. 30, 2021
Related Party Transactions [Abstract]
Related party transactions	13. Balances and transactions between the Company and its subsidiaries, which are related parties of the Company, have been eliminated on consolidation and are not disclosed in this note. Details of transactions between the Company and other related parties are disclosed below and in other notes accordingly to the nature of the transactions. All material transactions with and balances owed to SALP are disclosed in notes 9 and 10, where the transactions are disclosed and otherwise in this note. These transactions have been recorded at the exchange amount, meaning the amount agreed to between the parties. During the quarter and six months ended June 30, 2021, the Company recorded an interest expense of $1,054 and $2,091, and paid interest of $nil and $973, respectively on its loans with its parent, SALP. For the quarter and six months ended June 30, 2020, the Company recorded an interest expense of $311 and $619 and paid interest of $252 and $503, respectively. During the quarter and six months ended June 30, 2021, the Company also recorded $145 in legal expenses ($nil for the quarter and six months ended June 30, 2020), incurred by SALP that it is required to reimburse pursuant to certain indemnification obligations under the subscription agreement it signed with SALP on April 14, 2019.

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2021
Disclosure Of Nonadjusting Events After Reporting Period [Abstract]
Subsequent Events	1 4 . Subsequent events On July 9, 2021, the Company closed the sale of PBP, its plasma derived therapeutics’ manufacturing facility to Kedrion for US$9.1 million, subject to closing adjustments. On August 6, 2021, the Company’s subsidiary PBT, entered into a definitive agreement for the sale of the PRV it received on June 4, 2021 in conjunction with the FDA approval of it Biologics License Application for Ryplazim ®

Significant accounting polici_2

Significant accounting policies (Policies)	6 Months Ended
	Jun. 30, 2021
Significant Accounting Policies [Abstract]
Accounting framework	a) Accounting framework These interim financial statements have been prepared in accordance with IAS 34, Interim financial reporting These interim financial statements were approved for issue on August 15, 2021 by the Company’s Audit, Risk and Finance committee as delegated by the Board of Directors.
New standards and interpretations adopted	b) New standards and interpretations adopted The accounting policies used in these interim financial statements are consistent with those applied by the Company in its December 31, 2020 audited annual consolidated financial statements except for the adoption of the following amendment on January 1, 2021. Amendment to IFRS 16 Leases or - IFRS 16 has been revised to incorporate an amendment issued by the IASB in May 2020. The amendment permits lessees not to assess whether particular COVID-19-related rent concessions are lease modifications and, instead, account for those rent concessions as if they were not lease modifications. In addition, the amendment to IFRS 16 provides specific disclosure requirements regarding COVID-19-related rent concessions. The adoption of this amendment had no impact on the interim financial statements since the Company has not benefited from COVID-19 related rent concessions.
New standards and interpretations not yet adopted	c) New standards and interpretations not yet adopted The IFRS accounting standards, amendments, and interpretations that the Company reasonably expects may have a material impact on the disclosures, the financial position or results of operations of the Company when applied at a future date are as follows: Amendments to IAS 1, Presentation of Financial Statements (IAS 1) and IAS 8, Accounting policies, Changes in Accounting Estimates and Errors (IAS 8) The amendments to IAS 1 require entities to disclose their material accounting policies rather than their significant accounting policies and provides guidance to apply materiality judgments to accounting policy disclosure. The amendments to IAS 8 introduce a definition of accounting estimates and provide clarifications to distinguish accounting policies from accounting estimates. The amendments are effective for annual reporting periods beginning on or after January 1, 2023 with earlier application permitted. The Company is evaluating the impact of these changes on its financial statements.
Significant accounting judgements and critical accounting estimates	d ) Significant accounting judgements and critical accounting estimates The preparation of the interim consolidated financial statements requires the use of judgments, estimates and assumptions that affect the reported amounts of revenues, expenses, assets and liabilities and the accompanying disclosures. The uncertainty that is often inherent in these estimates and assumptions could result in material adjustments to assets or liabilities affected in future periods. The significant accounting judgments and critical accounting estimates applied by the Company, disclosed in the audited annual consolidated financial statements for the year ended December 31, 2020, remain unchanged.

Assets and Liabilities Held f_2

Assets and Liabilities Held for Sale and Discontinued Operations (Tables)	6 Months Ended
	Jun. 30, 2021
Disclosure Of Assets And Liabilities Held For Sale And Discontinued Operations [Abstract]
Summary of Assets, Liabilities and Other Comprehensive Income Pertaining to Disposal Group and Classified as Held for Sale	The major classes of assets, liabilities and accumulated other comprehensive income pertaining to the disposal group and classified as held for sale are as follows: Accounts receivable $ 1,503 Inventories 4,571 Prepaids 322 Other long-term assets 50 Capital assets 9,303 Intangible assets 8,657 Right-of-use assets 3,864 Total assets of disposal group held for sale 28,270 Accounts payable and accrued liabilities 3,151 Current portion of lease liabilities 989 Long-term portion of lease liabilities 3,955 Total liabilities of disposal group held for sale 8,095
Summary of Results and Cash Flows from Discontinued Operations	The net loss from the discontinued operations for the quarters and six months ended June 30, 2021 and 2020 are follows: Quarter ended June 30, Six months ended June 30, 2021 2020 2021 2020 Plasma-derived therapeutics segment: Revenues $ 423 $ 504 $ 949 $ 1,405 Expenses Cost of sales and other production expenses 750 468 1,456 1,104 Research and development expenses 1) 27,992 11,806 32,355 24,824 Administration expenses 1,095 1,348 2,190 2,943 Gain on foreign exchange (4 ) (27 ) (138 ) (1 ) Finance costs 823 1,565 2,166 2,958 Gain on extinguishment of liabilities — — — (79 ) Current income taxes 1 3 1 3 Loss from discontinued operations, net of income taxes $ (30,234 ) $ (14,659 ) $ (37,081 ) $ (30,347 ) 1) The cost of an onerous contract (note 8) is included in research and development expenses for the quarter and six months ended June 30, 2021. The cash flows from discontinued operations for the quarters and six months ended June 30, 2021 and 2020 are as follows: June 30, 2021 June 30, 2020 Bioseparations activities Cash flows from investing activities $ — $ 388 Cash generated during the period $ — $ 388 Plasma-derived therapeutic activities Cash flows from in operating activities 1) $ 4,734 $ 5,265 Cash flows used in financing activities (3,469 ) (3,192 ) Cash flows from (used) in investing activities 20,250 (222 ) Net effect of currency exchange rate on cash (31 ) 89 Cash flows generated during the period $ 21,484 $ 1,940 Total cash flows generated from discontinued operations $ 21,484 $ 2,328 1)
Summary of Gain on Sale of Subsidiaries	The details of the gain on sale of subsidiaries during the quarter ended June 30, 2021 is provided in the table below. Sale of plasma collection entities Fair value of the consideration received and receivable $ 12,826 Less: Carrying amount of net assets sold 10,849 Transaction costs 204 Reclassification of foreign currency translation reserve from other comprehensive income into the statement of operations (44 ) Gain on sale of plasma collection entities 1,817 Sale of Ryplazim entities Fair value of proceeds received or receivable at June 30, 2021 9,084 Less: Transaction costs 203 Gain on sale of Ryplazim entities recognized at June 30, 2021 8,881 Gain on sale of subsidiaries, net of income taxes $nil $ 10,698
Summary of Carrying Amounts of Assets and Liabilities Sold	The carrying amounts of the assets and liabilities sold as part of the sale of the plasma collection centers are as follows: Accounts receivable $ 137 Inventories 8,441 Prepaids 21 Other long-term assets 54 Capital assets 2,376 Right-of-use assets 2,000 Intangible assets 1,092 Total assets $ 14,121 Accounts payable and accrued liabilities 639 Deferred revenue - Current portion of lease liabilities 665 Long-term portion of lease liabilities 1,968 Total liabilities $ 3,272 Net assets sold $ 10,849

Capital Assets (Tables)

Capital Assets (Tables)	6 Months Ended
	Jun. 30, 2021
Disclosure Of Property Plant And Equipment [Abstract]
Summary of Capital Assets	Production Furniture and Land and Leasehold and laboratory computer Buildings improvements equipment equipment Total Cost Balance at January 1, 2021 $ 4,567 $ 7,349 $ 29,904 $ 3,365 $ 45,185 Additions — — 60 4 64 Disposals — (399 ) (1,420 ) (301 ) (2,120 ) Sold - discontinued operations (note 3) — (1,921 ) (973 ) (212 ) (3,106 ) Effect of foreign exchange differences — (107 ) (45 ) (9 ) (161 ) Reclassified to assets held for sale (note 3) — (4,403 ) (20,552 ) (1,875 ) (26,830 ) Balance at June 30, 2021 $ 4,567 $ 519 $ 6,974 $ 972 $ 13,032 Accumulated depreciation Balance at January 1, 2021 $ 804 $ 2,901 $ 20,208 $ 2,481 $ 26,394 Depreciation expense 96 242 586 197 1,121 Disposals — (400 ) (1,236 ) (303 ) (1,939 ) Sold - discontinued operations (note 3) — (273 ) (335 ) (122 ) (730 ) Effect of foreign exchange differences — (12 ) (8 ) (5 ) (25 ) Reclassified to assets held for sale (note 3) — (2,121 ) (13,923 ) (1,483 ) (17,527 ) Balance at June 30, 2021 $ 900 $ 337 $ 5,292 $ 765 $ 7,294 Carrying amounts At June 30, 2021 $ 3,667 $ 182 $ 1,682 $ 207 $ 5,738 At December 31, 2020 3,763 4,448 9,696 884 18,791

Right-of-use Assets (Tables)

Right-of-use Assets (Tables)	6 Months Ended
	Jun. 30, 2021
Disclosure Of Quantitative Information About Rightofuse Assets [Abstract]
Summary of Quantitative Information About Right-Of-Use Assets	Production and laboratory Buildings equipment Other Total Net book value as at January 1, 2021 $ 8,086 $ 426 $ 45 $ 8,557 Lease modifications and other remeasurements (8 ) 1 (11 ) (18 ) Sold - discontinued operations (note 3) (1,717 ) (272 ) (11 ) (2,000 ) Depreciation expense (642 ) (83 ) (11 ) (736 ) Effect of foreign exchange differences (78 ) (6 ) (5 ) (89 ) Reclassified to assets held for sale (note 3) (3,791 ) (66 ) (7 ) (3,864 ) Net book value at June 30, 2021 $ 1,850 $ — $ — $ 1,850

Intangible Assets (Tables)

Intangible Assets (Tables)	6 Months Ended
	Jun. 30, 2021
Disclosure Of Intangible Assets [Abstract]
Summary of Intangible Assets	Licenses and other rights Patents Software Total Cost Balance at January 1, 2021 $ 162,064 $ 6,783 $ 3,306 $ 172,153 Additions — 93 (1 ) 92 Disposals — (12 ) — (12 ) Sold - discontinued operations (note 3) (1,268 ) — (345 ) (1,613 ) Effect of foreign exchange differences 1 (19 ) (19 ) (37 ) Reclassified to assets held for sale (note 3) (13,739 ) (1,393 ) (2,122 ) (17,254 ) Balance at June 30, 2021 $ 147,058 $ 5,452 $ 819 $ 153,329 Accumulated amortization Balance at January 1, 2021 $ 150,528 $ 4,429 $ 1,704 $ 156,661 Amortization expense 109 534 279 922 Disposals — (3 ) (1 ) (4 ) Sold - discontinued operations (note 3) (433 ) — (88 ) (521 ) Impairments — 341 — 341 Effect of foreign exchange differences 18 (22 ) (7 ) (11 ) Reclassified to assets held for sale (note 3) (6,861 ) (507 ) (1,229 ) (8,597 ) Balance at June 30, 2021 $ 143,361 $ 4,772 $ 658 $ 148,791 Carrying amounts At June 30, 2021 $ 3,697 $ 680 $ 161 $ 4,538 At December 31, 2020 11,536 2,354 1,602 15,492

Lease Liabilities (Tables)

Lease Liabilities (Tables)	6 Months Ended
	Jun. 30, 2021
Lease Liabilities [Abstract]
Summary of Lease Liabilities	Balance at January 1, 2021 $ 33,452 Additions — Interest expense 2,636 Payments (5,003 ) Derecognized - discontinued operations (note 3) (2,633 ) Lease modification and other remeasurements 1,058 Effect of foreign exchange differences (430 ) Reclassified to liabilities held for sale (4,944 ) Balance at June 30 $ 24,136 Less current portion of lease liabilities 4,807 Long-term portion of lease liabilities $ 19,329

Provisions (Tables)

Provisions (Tables)	6 Months Ended
	Jun. 30, 2021
Restructuring Provision [Abstract]
Summary of Provisions	Provision recognized during the period $ 21,928 Less current portion of provisions 3,078 Long-term portion of provisions $ 18,850

Warrant Liability (Tables)

Warrant Liability (Tables)	6 Months Ended
	Jun. 30, 2021
Warrant Liability [Abstract]
Schedule of Fair Value of Warrants	The fair value of the November 2020 warrants on the various dates discussed above was calculated using a Black-Scholes option pricing model in a Monte Carlo simulation in order to evaluate the downward adjustment mechanism to the exercise price. The assumptions used at the different valuation dates are provided in the table below: June 30, December 31, 2021 2020 Underlying common share fair value (in US$) $ 3.89 $ 4.20 Remaining life until expiry 4.3 4.8 Volatility 51.0 % 49.0 % Risk-free interest rate 0.75 % 0.34 % Expected dividend rate — — Fair value of a warrant calculated using a Black-Sholes pricing model (in US$) $ 1.22 $ 1.41 Fair value of exercise price adjustment mechanism (in US$) $ 0.21 $ 0.22 Illiquidity discount 28.0 % 29.0 % Fair value of a warrant (in US$) $ 1.03 $ 1.16 Fair value of a warrant (in CA$) $ 1.28 $ 1.47

Long-term Debt (Tables)

Long-term Debt (Tables)	6 Months Ended
	Jun. 30, 2021
Disclosure Of Detailed Information About Borrowings [Abstract]
Summary of Long-term Debt	Balance at January 1, 2021 $ 40,532 Stated and accreted interest 2,191 Repayment of stated interest (973 ) Balance at June 30, 2021 $ 41,750
Summary of Carrying Value of Long-term Debt	At June 30, 2021, the carrying amount of the debt comprised the following loans: First term loan having a principal of $10,000 maturing on April 23, 2024 bearing stated interest of 8% per annum (effective interest rate of 15.05%) 1) $ 9,295 Second term loan having a principal of $29,123 maturing on April 23, 2024 bearing stated interest of 10% per annum (effective interest rate of 10.47%) 1) 29,855 Secured convertible debentures having an aggregate principal amount of $2,410 maturing on March 31, 2022 bearing stated interest of 8% per annum (effective interest rate of 8.24%) 2) 2,600 $ 41,750 Less current portion of long-term debt (2,600 ) Long-term portion of long-term debt $ 39,150 1) 2) The secured convertible debentures are secured by all the assets of Fairhaven. The Company’s security interest created pursuant to its consolidated loan agreement with SALP, its parent, is subordinated to the security interest on the Fairhaven assets.

Share Capital and Other Equit_2

Share Capital and Other Equity Instruments (Tables)	6 Months Ended
	Jun. 30, 2021
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Schedule of Changes in Issued and Outstanding Common Share or RSU or Warrants	Changes in the issued and outstanding common shares of the Company during the quarters ended June 30, 2021 and 2020 were as follows: June 30, 2021 June 30, 2020 Number Amount Number Amount Balance - beginning of period 29,943,839 $ 977,261 23,313,164 $ 932,951 Issued to acquire assets — — 96,833 1,240 Shares issued pursuant to a restricted share units plan (note 11b) — — 10,355 9,764 Balance - end of period 29,943,839 $ 977,261 23,420,352 $ 943,955
Schedule of Changes in Number of Stock Options Outstanding and Weighted Average Exercise Price	For stock options having a CA$ exercise price, the changes in the number of stock options outstanding during the quarters ended June 30, 2021 and 2020 were as follows: June 30, 2021 June 30, 2020 Weighted Weighted average average exercise price exercise price Number (in CA$) Number (in CA$) Balance - beginning of period 2,485,555 $ 18.70 2,209,864 $ 38.72 Granted — — 436,570 14.06 Forfeited (850,274 ) 15.11 (64,141 ) 24.42 Expired — — (1,435 ) 2,433.20 Repriced - options before repricing — — (1,929,685 ) 35.14 Repriced - options after repricing — — 1,929,685 15.21 Balance - end of period 1,635,281 $ 20.56 2,580,858 $ 18.67 For stock options having a US$ exercise price, the changes in the number of stock options outstanding during the quarter ended June 30, 2021 were as follows: June 30, 2021 Weighted average exercise price Number (in US$) Balance - beginning of period 305,000 $ 4.70 Granted 90,000 4.65 Balance - end of period 395,000 $ 4.69
Summary of Weighted Average Inputs into Model and Resulting Grant Date Fair Values	The Company uses the Black-Scholes option pricing model to calculate the fair value of stock options at the date of grant. The weighted average inputs into the model and the resulting grant date fair values during the six months ended June 30, 2021 were as follows: Expected dividend rate — Expected volatility of share price 115.5 % Risk-free interest rate 0.99 % Expected life in years 6.5 Weighted average grant date fair value $ 5.00 Expected dividend rate — Expected volatility of share price 93.2 % Risk-free interest rate 0.4 % Expected life in years 6.3 Weighted average grant date incremental fair value $ 1.55
Schedule of Stock Options Issued and Outstanding by Range of Exercise Price	At June 30, 2021, stock options issued and outstanding denominated in CA$ and US$ by range of exercise price are as follows: Weighted average Weighted Weighted Range of exercise remaining average average price for stock option Number contractual life exercise price Number exercise price issued in CA$ outstanding (in years) (CA$) exercisable (CA$) $7.86 - $11.99 171,250 8.3 $ 9.58 68,672 $ 9.73 $ 14.06 323,926 8.9 14.06 112,972 14.06 $ 15.21 1,083,328 7.9 15.21 580,241 15.21 $27.00 - $3,170.00 56,777 7.6 192.87 56,303 189.91 1,635,281 8.2 $ 20.56 818,188 $ 26.61 Weighted average Weighted Weighted Range of exercise remaining average average price for stock option Number contractual life exercise price Number exercise price issued in US$ outstanding (in years) (US$) exercisable (US$) $4.09 - $5.34 375,000 9.5 $ 4.36 165,000 $ 4.37 $ 10.80 20,000 9.3 10.80 3,333 10.80 395,000 9.5 $ 4.69 168,333 $ 4.50
Schedule of Total Share-Based Payments Expense	The total share-based payments expense, comprising the above-mentioned expenses for stock options and RSU, has been included in the consolidated statements of operations for the quarter and six months ended June 30, 2021 and 2020 as indicated in the following table: Quarter ended June 30, Six months ended June 30, 2021 2020 2021 2020 Research and development expenses $ 467 $ 904 $ 437 $ 1,920 Administration, selling and marketing expenses 899 1,340 1,873 2,696 Loss from discontinued operations (409 ) 180 (444 ) 185 $ 957 $ 2,424 $ 1,866 $ 4,801
Restricted Stock Units
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Schedule of Changes in Issued and Outstanding Common Share or RSU or Warrants	Changes in the number of restricted share units or RSU outstanding during the six months ended June 30, 2021 and 2020 were as follows: June 30, June 30, 2021 2020 Balance - beginning of period 4,216 17,565 Forfeited (4,048 ) (24 ) Released — (10,355 ) Paid in cash (144 ) (2,948 ) Balance - end of period 24 4,238
Warrants
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Schedule of Changes in Issued and Outstanding Common Share or RSU or Warrants	There were no changes in the number of warrants having a CA$ exercise price during the six months ended June 30, 2021 and 2020. At June 30, 2021 and 2020, the number of warrants outstanding by exercise price were as follows: June 30, 2021 June 30, 2020 Weighted Weighted average average exercise price exercise price Number (CA$) Number (CA$) Balance of warrants - end of period 172,735 $ 84.33 172,735 $ 84.33 June 30, 2021 Weighted average exercise price Number (US$) Balance of warrants - end of period 7,894,734 $ 5.50
Schedule of Warrants Outstanding, Exercise Price, Expiry Rate and Overall Weighted Average Exercise Price	At June 30, 2021, the weighted average exercise prices (in CA$ or in US$) and expiry dates for the warrants outstanding are as follows: Number Expiry date Exercise price (CA$) 4,000 January 2023 3,000.00 168,735 April 2027 15.21 Warrants outstanding with an exercise price in CA$ 172,735 $ 84.33 Number Expiry date Exercise price (US$) Warrants outstanding with an exercise price in US$ 7,894,734 November 2025 $ 5.50

Government Grants (Tables)

Government Grants (Tables)	6 Months Ended
	Jun. 30, 2021
Disclosure Of Government Grants [Abstract]
Summary of Government Grants	These government grants were recorded as a reduction of salary and rent expenses and are recognized as follows in the consolidated statement of operations: Quarter ended June 30, Six months ended June 30, 2021 2020 2021 2020 Research and development expenses $ 149 $ 460 $ 512 $ 460 Administration expenses 115 584 411 584 Loss from discontinued operations 940 1,901 3,182 1,901 $ 1,204 $ 2,945 $ 4,105 $ 2,945

Nature of Operations and Goin_2

Nature of Operations and Going Concern - Additional Information (Details) $ in Thousands, $ in Millions	Jun. 04, 2021USD ($)	Jun. 30, 2021CAD ($)	Jun. 30, 2020CAD ($)	Jun. 30, 2021CAD ($)	Jun. 30, 2020CAD ($)	Dec. 31, 2020CAD ($)
Disclosure Of Nature Of Operations And Going Concern [Line Items]
Net loss		$ 32,133	$ 27,816	$ 52,982	$ 55,473
Operating cash flows				29,647	$ 31,937
Working capital		38,300		38,300		$ 49,200
Accumulated deficit		$ 1,139,354		$ 1,139,354		$ 1,087,049
Prometic Biotherapeutics Inc
Disclosure Of Nature Of Operations And Going Concern [Line Items]
Purchase price received	$ 105
PRV | Definitive Agreement for Sale | Discontinued Operations
Disclosure Of Nature Of Operations And Going Concern [Line Items]
Percentage of net proceeds from subsidiaries	30.00%
PRV | Prometic Biotherapeutics Inc
Disclosure Of Nature Of Operations And Going Concern [Line Items]
Purchase price received	$ 105

Assets and Liabilities Held f_3

Assets and Liabilities Held for Sale and Discontinued Operations - Additional Information (Details) $ in Thousands, $ in Millions	Aug. 06, 2021USD ($)	Jul. 09, 2021CAD ($)	Jul. 09, 2021USD ($)	Jun. 04, 2021USD ($)	Nov. 25, 2019OperatingSegment	Jun. 30, 2021CAD ($)	Jun. 30, 2020CAD ($)	Jun. 30, 2021CAD ($)	Jun. 30, 2020CAD ($)
Disclosure Of Analysis Of Single Amount Of Discontinued Operations [Line Items]
Loss from discontinued operations, net of income taxes (note 3)						$ (30,234)	$ (14,659)	$ (37,081)	$ (30,347)
Discontinued Operations
Disclosure Of Analysis Of Single Amount Of Discontinued Operations [Line Items]
Number of operations sold | OperatingSegment					2
Loss from discontinued operations, net of income taxes (note 3)						$ (30,234)	$ (14,659)	$ (37,081)	$ (30,347)
Definitive Agreement for Sale | PRV | Discontinued Operations
Disclosure Of Analysis Of Single Amount Of Discontinued Operations [Line Items]
Percentage of net proceeds from subsidiaries				30.00%
Prometic Biotherapeutics Inc
Disclosure Of Analysis Of Single Amount Of Discontinued Operations [Line Items]
Purchase price received				$ 105
Prometic Biotherapeutics Inc | PRV
Disclosure Of Analysis Of Single Amount Of Discontinued Operations [Line Items]
Purchase price received				$ 105
Prometic Biotherapeutics Inc | Definitive Agreement for Sale | PRV
Disclosure Of Analysis Of Single Amount Of Discontinued Operations [Line Items]
Upfront payment received	$ 105
Upfront payment received, net of selling costs	$ 103.5
Prometic Bioproduction Inc | Definitive Agreement for Sale | Discontinued Operations
Disclosure Of Analysis Of Single Amount Of Discontinued Operations [Line Items]
Purchase price received		$ 9,100
SPA | Definitive Agreement for Sale | Discontinued Operations
Disclosure Of Analysis Of Single Amount Of Discontinued Operations [Line Items]
Proceeds from sale of subsidiary			$ 5.2
PRV | Definitive Agreement for Sale | Discontinued Operations
Disclosure Of Analysis Of Single Amount Of Discontinued Operations [Line Items]
Percentage of net proceeds from subsidiaries		30.00%	30.00%

Assets and Liabilities Held f_4

Assets and Liabilities Held for Sale and Discontinued Operations - Summary of Assets, Liabilities and Other Comprehensive Income Pertaining to Disposal Group and Classified as Held for Sale (Details) - CAD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Disclosure Of Assets And Liabilities Held For Sale [Line Items]
Inventories		$ 9,377
Prepaids	$ 6,668	14,486
Other long-term assets	285	1,353
Capital assets (note 4)	5,738	18,791
Intangible assets (note 6)	4,538	15,492
Right-of-use assets (note 5)	1,850	8,557
Total assets	79,219	117,784
Accounts payable and accrued liabilities	9,375	16,835
Current portion of lease liabilities	4,807	6,946
Long-term portion of lease liabilities	19,329	26,506
Total liabilities	115,471	$ 102,772
Disposal Groups Classified as Held for Sale
Disclosure Of Assets And Liabilities Held For Sale [Line Items]
Accounts receivable	1,503
Inventories	4,571
Prepaids	322
Other long-term assets	50
Capital assets (note 4)	9,303
Intangible assets (note 6)	8,657
Right-of-use assets (note 5)	3,864
Total assets	28,270
Accounts payable and accrued liabilities	3,151
Current portion of lease liabilities	989
Long-term portion of lease liabilities	3,955
Total liabilities	$ 8,095

Assets and Liabilities Held f_5

Assets and Liabilities Held for Sale and Discontinued Operations - Summary of Net Loss From Discontinued Operations (Details) - CAD ($) $ in Thousands		3 Months Ended			6 Months Ended
		Jun. 30, 2021	Mar. 31, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Disclosure Of Analysis Of Single Amount Of Discontinued Operations [Line Items]
Revenues		$ 25		$ 36	$ 235	$ 238
Expenses
Administration expenses		8,551		8,503	16,688	17,580
Finance costs		1,661		287	2,833	524
Gain on extinguishment of liabilities			$ (79)
Loss from discontinued operations, net of income taxes		(30,234)		(14,659)	(37,081)	(30,347)
Discontinued Operations
Disclosure Of Analysis Of Single Amount Of Discontinued Operations [Line Items]
Revenues		423		504	949	1,405
Expenses
Cost of sales and other production expenses		750		468	1,456	1,104
Research and development expenses	[1]	27,992		11,806	32,355	24,824
Administration expenses		1,095		1,348	2,190	2,943
Gain on foreign exchange		(4)		(27)	(138)	(1)
Finance costs		823		1,565	2,166	2,958
Gain on extinguishment of liabilities						(79)
Current income taxes		1		3	1	3
Loss from discontinued operations, net of income taxes		$ (30,234)		$ (14,659)	$ (37,081)	$ (30,347)
[1]	The cost of an onerous contract (note 8) is included in research and development expenses for the quarter and six months ended June 30, 2021.

Assets and Liabilities Held f_6

Assets and Liabilities Held for Sale and Discontinued Operations - Summary of Cash Flows from Discontinued Operations (Details) - CAD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Disclosure Of Analysis Of Single Amount Of Discontinued Operations [Line Items]
Net effect of currency exchange rate on cash and cash equivalents	$ (704)	$ 1,431
Discontinued Operations | Bioseparations Activities
Disclosure Of Analysis Of Single Amount Of Discontinued Operations [Line Items]
Cash flows from investing activities		388
Cash generated during the period		388
Discontinued Operations | Plasma-derived Therapeutic Activities
Disclosure Of Analysis Of Single Amount Of Discontinued Operations [Line Items]
Cash flows used in operating activities	4,734	5,265
Cash flows used in financing activities	(3,469)	(3,192)
Cash flows from investing activities	20,250	(222)
Net effect of currency exchange rate on cash and cash equivalents	(31)	89
Cash flows generated during the period	21,484	1,940
Total cash flows generated from discontinued operations	$ 21,484	$ 2,328

Assets and Liabilities Held f_7

Assets and Liabilities Held for Sale and Discontinued Operations - Summary of Gain on Sale of Subsidiaries (Details) - CAD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Disclosure Of Analysis Of Single Amount Of Discontinued Operations [Line Items]
Loss from discontinued operations, net of income taxes (note 3)	$ (30,234)	$ (14,659)	$ (37,081)	$ (30,347)
Gain on sale of subsidiaries, net of income taxes $nil	10,698		10,698
Discontinued Operations
Disclosure Of Analysis Of Single Amount Of Discontinued Operations [Line Items]
Loss from discontinued operations, net of income taxes (note 3)	(30,234)	$ (14,659)	(37,081)	$ (30,347)
Discontinued Operations | Plasma Collection Entities
Disclosure Of Analysis Of Single Amount Of Discontinued Operations [Line Items]
Fair value of the consideration received and receivable	12,826		12,826
Carrying amount of net assets sold	10,849		10,849
Transaction costs	204
Reclassification of foreign currency translation reserve from other comprehensive income into the statement of operations	(44)
Loss from discontinued operations, net of income taxes (note 3)	1,817
Discontinued Operations | Ryplazim Entities
Disclosure Of Analysis Of Single Amount Of Discontinued Operations [Line Items]
Transaction costs	203
Loss from discontinued operations, net of income taxes (note 3)	8,881
Fair value of proceeds received or receivable at June 30, 2021	$ 9,084		$ 9,084

Assets and Liabilities Held f_8

Assets and Liabilities Held for Sale and Discontinued Operations - Summary of Gain on Sale of Subsidiaries (Parenthetical) (Details)	3 Months Ended
	Jun. 30, 2021CAD ($)
Discontinued Operations
Disclosure Of Analysis Of Single Amount Of Discontinued Operations [Line Items]
Income tax

Assets and Liabilities Held f_9

Assets and Liabilities Held for Sale and Discontinued Operations - Summary of Carrying Amounts of Assets and Liabilities Sold (Details) - CAD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Disclosure Of Analysis Of Single Amount Of Discontinued Operations [Line Items]
Inventories		$ 9,377
Prepaids	$ 6,668	14,486
Other long-term assets	285	1,353
Capital assets (note 4)	5,738	18,791
Right-of-use assets (note 5)	1,850	8,557
Intangible assets (note 6)	4,538	15,492
Total assets	79,219	117,784
Accounts payable and accrued liabilities	9,375	16,835
Current portion of lease liabilities	4,807	6,946
Long-term portion of lease liabilities	19,329	26,506
Total liabilities	115,471	$ 102,772
Discontinued Operations | Plasma Collection Entities
Disclosure Of Analysis Of Single Amount Of Discontinued Operations [Line Items]
Accounts receivable	137
Inventories	8,441
Prepaids	21
Other long-term assets	54
Capital assets (note 4)	2,376
Right-of-use assets (note 5)	2,000
Intangible assets (note 6)	1,092
Total assets	14,121
Accounts payable and accrued liabilities	639
Current portion of lease liabilities	665
Long-term portion of lease liabilities	1,968
Total liabilities	3,272
Net assets sold	$ 10,849

Capital Assets - Summary of Cap

Capital Assets - Summary of Capital Assets (Details) $ in Thousands	6 Months Ended
	Jun. 30, 2021CAD ($)
Disclosure Of Property Plant And Equipment [Line Items]
Beginning balance	$ 18,791
Ending balance	5,738
Cost
Disclosure Of Property Plant And Equipment [Line Items]
Beginning balance	45,185
Additions	64
Disposals	(2,120)
Sold - discontinued operations (note 3)	(3,106)
Effect of foreign exchange differences	(161)
Reclassified to assets held for sale (note 3)	(26,830)
Ending balance	13,032
Accumulated Depreciation
Disclosure Of Property Plant And Equipment [Line Items]
Beginning balance	26,394
Depreciation expense	1,121
Disposals	(1,939)
Sold - discontinued operations (note 3)	(730)
Effect of foreign exchange differences	(25)
Reclassified to assets held for sale (note 3)	(17,527)
Ending balance	7,294
Land and Buildings
Disclosure Of Property Plant And Equipment [Line Items]
Beginning balance	3,763
Ending balance	3,667
Land and Buildings | Cost
Disclosure Of Property Plant And Equipment [Line Items]
Beginning balance	4,567
Ending balance	4,567
Land and Buildings | Accumulated Depreciation
Disclosure Of Property Plant And Equipment [Line Items]
Beginning balance	804
Depreciation expense	96
Ending balance	900
Leasehold Improvements
Disclosure Of Property Plant And Equipment [Line Items]
Beginning balance	4,448
Ending balance	182
Leasehold Improvements | Cost
Disclosure Of Property Plant And Equipment [Line Items]
Beginning balance	7,349
Disposals	(399)
Sold - discontinued operations (note 3)	(1,921)
Effect of foreign exchange differences	(107)
Reclassified to assets held for sale (note 3)	(4,403)
Ending balance	519
Leasehold Improvements | Accumulated Depreciation
Disclosure Of Property Plant And Equipment [Line Items]
Beginning balance	2,901
Depreciation expense	242
Disposals	(400)
Sold - discontinued operations (note 3)	(273)
Effect of foreign exchange differences	(12)
Reclassified to assets held for sale (note 3)	(2,121)
Ending balance	337
Production and Laboratory Equipment
Disclosure Of Property Plant And Equipment [Line Items]
Beginning balance	9,696
Ending balance	1,682
Production and Laboratory Equipment | Cost
Disclosure Of Property Plant And Equipment [Line Items]
Beginning balance	29,904
Additions	60
Disposals	(1,420)
Sold - discontinued operations (note 3)	(973)
Effect of foreign exchange differences	(45)
Reclassified to assets held for sale (note 3)	(20,552)
Ending balance	6,974
Production and Laboratory Equipment | Accumulated Depreciation
Disclosure Of Property Plant And Equipment [Line Items]
Beginning balance	20,208
Depreciation expense	586
Disposals	(1,236)
Sold - discontinued operations (note 3)	(335)
Effect of foreign exchange differences	(8)
Reclassified to assets held for sale (note 3)	(13,923)
Ending balance	5,292
Furniture and Computer Equipment
Disclosure Of Property Plant And Equipment [Line Items]
Beginning balance	884
Ending balance	207
Furniture and Computer Equipment | Cost
Disclosure Of Property Plant And Equipment [Line Items]
Beginning balance	3,365
Additions	4
Disposals	(301)
Sold - discontinued operations (note 3)	(212)
Effect of foreign exchange differences	(9)
Reclassified to assets held for sale (note 3)	(1,875)
Ending balance	972
Furniture and Computer Equipment | Accumulated Depreciation
Disclosure Of Property Plant And Equipment [Line Items]
Beginning balance	2,481
Depreciation expense	197
Disposals	(303)
Sold - discontinued operations (note 3)	(122)
Effect of foreign exchange differences	(5)
Reclassified to assets held for sale (note 3)	(1,483)
Ending balance	$ 765

Right-of-use Assets - Summary o

Right-of-use Assets - Summary of Quantitative Information About Right-Of-Use Assets (Details) - CAD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Disclosure Of Quantitative Information About Rightofuse Assets [Line Items]
Net book value as at January 1, 2021	$ 8,557
Lease modifications and other remeasurements	(18)
Sold - discontinued operations (note 3)	(2,000)
Depreciation expense	(736)	$ (2,264)
Effect of foreign exchange differences	(89)
Reclassified to assets held for sale (note 3)	(3,864)
Net book value at June 30, 2021	1,850
Buildings
Disclosure Of Quantitative Information About Rightofuse Assets [Line Items]
Net book value as at January 1, 2021	8,086
Lease modifications and other remeasurements	(8)
Sold - discontinued operations (note 3)	(1,717)
Depreciation expense	(642)
Effect of foreign exchange differences	(78)
Reclassified to assets held for sale (note 3)	(3,791)
Net book value at June 30, 2021	1,850
Production and Laboratory Equipment
Disclosure Of Quantitative Information About Rightofuse Assets [Line Items]
Net book value as at January 1, 2021	426
Lease modifications and other remeasurements	1
Sold - discontinued operations (note 3)	(272)
Depreciation expense	(83)
Effect of foreign exchange differences	(6)
Reclassified to assets held for sale (note 3)	(66)
Other
Disclosure Of Quantitative Information About Rightofuse Assets [Line Items]
Net book value as at January 1, 2021	45
Lease modifications and other remeasurements	(11)
Sold - discontinued operations (note 3)	(11)
Depreciation expense	(11)
Effect of foreign exchange differences	(5)
Reclassified to assets held for sale (note 3)	$ (7)

Intangible Assets - Summary of

Intangible Assets - Summary of Intangible Assets (Details) - CAD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Disclosure Of Intangible Assets [Line Items]
Beginning balance	$ 15,492
Amortization of intangible assets (note 6)	922	$ 494
Ending balance	4,538
Cost
Disclosure Of Intangible Assets [Line Items]
Beginning balance	172,153
Additions	92
Disposals	(12)
Sold - discontinued operations	(1,613)
Effect of foreign exchange differences	(37)
Reclassified to assets held for sale (note 3)	(17,254)
Ending balance	153,329
Accumulated Amortization
Disclosure Of Intangible Assets [Line Items]
Beginning balance	156,661
Amortization of intangible assets (note 6)	922
Disposals	(4)
Sold - discontinued operations	(521)
Impairments	341
Effect of foreign exchange differences	(11)
Reclassified to assets held for sale (note 3)	(8,597)
Ending balance	148,791
Licenses and Other Rights
Disclosure Of Intangible Assets [Line Items]
Beginning balance	11,536
Ending balance	3,697
Licenses and Other Rights | Cost
Disclosure Of Intangible Assets [Line Items]
Beginning balance	162,064
Sold - discontinued operations	(1,268)
Effect of foreign exchange differences	1
Reclassified to assets held for sale (note 3)	(13,739)
Ending balance	147,058
Licenses and Other Rights | Accumulated Amortization
Disclosure Of Intangible Assets [Line Items]
Beginning balance	150,528
Amortization of intangible assets (note 6)	109
Sold - discontinued operations	(433)
Effect of foreign exchange differences	18
Reclassified to assets held for sale (note 3)	(6,861)
Ending balance	143,361
Patents
Disclosure Of Intangible Assets [Line Items]
Beginning balance	2,354
Ending balance	680
Patents | Cost
Disclosure Of Intangible Assets [Line Items]
Beginning balance	6,783
Additions	93
Disposals	(12)
Effect of foreign exchange differences	(19)
Reclassified to assets held for sale (note 3)	(1,393)
Ending balance	5,452
Patents | Accumulated Amortization
Disclosure Of Intangible Assets [Line Items]
Beginning balance	4,429
Amortization of intangible assets (note 6)	534
Disposals	(3)
Impairments	341
Effect of foreign exchange differences	(22)
Reclassified to assets held for sale (note 3)	(507)
Ending balance	4,772
Software
Disclosure Of Intangible Assets [Line Items]
Beginning balance	1,602
Ending balance	161
Software | Cost
Disclosure Of Intangible Assets [Line Items]
Beginning balance	3,306
Additions	(1)
Sold - discontinued operations	(345)
Effect of foreign exchange differences	(19)
Reclassified to assets held for sale (note 3)	(2,122)
Ending balance	819
Software | Accumulated Amortization
Disclosure Of Intangible Assets [Line Items]
Beginning balance	1,704
Amortization of intangible assets (note 6)	279
Disposals	(1)
Sold - discontinued operations	(88)
Effect of foreign exchange differences	(7)
Reclassified to assets held for sale (note 3)	(1,229)
Ending balance	$ 658

Intangible Assets - Additional

Intangible Assets - Additional Information (Details) $ in Thousands	6 Months Ended
	Jun. 30, 2021CAD ($)
Patents
Disclosure Of Intangible Assets [Line Items]
Impairments	$ 341

Lease Liabilities - Summary of

Lease Liabilities - Summary of Lease Liabilities (Details) - CAD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020
Disclosure Of Quantitative Information About Rightofuse Assets [Line Items]
Interest expense	$ 1,283	$ 1,604	$ 2,636	$ 3,153
Less current portion of lease liabilities	4,807		4,807		$ 6,946
Long-term portion of lease liabilities	19,329		19,329		$ 26,506
Lease Liabilities
Disclosure Of Quantitative Information About Rightofuse Assets [Line Items]
Balance at January 1, 2021			33,452
Interest expense			2,636
Payments			(5,003)
Derecognized - discontinued operations (note 3)			(2,633)
Lease modification and other remeasurements			1,058
Effect of foreign exchange differences			(430)
Reclassified to liabilities held for sale			(4,944)
Balance at June 30	24,136		24,136
Less current portion of lease liabilities	4,807		4,807
Long-term portion of lease liabilities	$ 19,329		$ 19,329

Lease Liabilities - Additional

Lease Liabilities - Additional Information (Details) - CAD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Lease Liabilities [Abstract]
Interest expense	$ 1,283	$ 1,604	$ 2,636	$ 3,153

Provisions - Additional Informa

Provisions - Additional Information (Details) $ in Thousands	Jun. 30, 2021CAD ($)
Disclosure Of Provision Matrix [Abstract]
Provision for onerous contract	$ 21,928

Provisions - Summary of Provisi

Provisions - Summary of Provisions (Details) $ in Thousands	Jun. 30, 2021CAD ($)
Restructuring Provision [Abstract]
Provision for onerous contract	$ 21,928
Less current portion of provisions	3,078
Long-term portion of provisions	$ 18,850

Warrant Liability - Additional

Warrant Liability - Additional Information (Details) $ in Thousands	Nov. 25, 2020shares	Nov. 03, 2020$ / shares	Jun. 30, 2021CAD ($)	Jun. 30, 2021CAD ($)shares	Dec. 31, 2020CAD ($)
Disclosure Of Detailed Information About Warrant Liability [Line Items]
Number of warrants issued | shares	7,894,734			0
Warrants expiration date				November 3, 2025
Warrant description				Each warrant can be exercised to acquire one common share at an exercise price initially set at US$5.50 and that can be reduced if equity financings are completed at a lower price before its expiry.
Warrants exercise price per share | $ / shares		$ 5.50
Fair value of warrant liability			$ 10,084	$ 10,084	$ 11,640
Change in fair value of warrant liability			1,402	1,556
SALP
Disclosure Of Detailed Information About Warrant Liability [Line Items]
Fair value of warrant liability			$ 5,042	$ 5,042	$ 5,820

Warrant Liability - Schedule of

Warrant Liability - Schedule of Fair Value of Warrants on Various Dates Calculated Using a Black-Scholes Option Pricing Model with Assumptions (Details)	May 26, 2020yr	Jun. 30, 2021yr$ / shares	Jun. 30, 2021yr$ / shares	Dec. 31, 2020yr$ / shares	Dec. 31, 2020yr$ / shares
Disclosure Of Detailed Information About Stock Option Assumption [Line Items]
Remaining life until expiry | yr	6.3	6.5	6.5
Volatility	93.20%	115.50%	115.50%
Risk-free interest rate	0.40%	0.99%	0.99%
Black Scholes Option Pricing Model
Disclosure Of Detailed Information About Stock Option Assumption [Line Items]
Underlying common share fair value (in US$)			$ 3.89		$ 4.20
Remaining life until expiry | yr		4.3	4.3	4.8	4.8
Volatility		51.00%	51.00%	49.00%	49.00%
Risk-free interest rate		0.75%	0.75%	0.34%	0.34%
Fair value of a warrant calculated using a Black-Sholes pricing model (in US$)			$ 1.22		$ 1.41
Fair value of exercise price adjustment mechanism (in US$)			$ 0.21		$ 0.22
Illiquidity discount		28.00%	28.00%	29.00%	29.00%
Fair value of a warrant | (per share)		$ 1.28	$ 1.03	$ 1.47	$ 1.16

Long-term Debt - Summary of Lon

Long-term Debt - Summary of Long-term Debt (Details) $ in Thousands	6 Months Ended
	Jun. 30, 2021CAD ($)
Disclosure Of Detailed Information About Borrowings [Abstract]
Balance at January 1, 2021	$ 40,532
Stated and accreted interest	2,191
Repayment of stated interest	(973)
Balance at June 30, 2021	$ 41,750

Long-term Debt - Summary of Car

Long-term Debt - Summary of Carrying Value of Long-term Debt (Details) - CAD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Disclosure Of Detailed Information About Borrowings [Line Items]
Borrowings	$ 41,750	$ 40,532
Less current portion of long-term debt	(2,600)
Long-term portion of long-term debt	39,150	$ 40,532
First Term Loan
Disclosure Of Detailed Information About Borrowings [Line Items]
Borrowings	9,295
Second Term Loan
Disclosure Of Detailed Information About Borrowings [Line Items]
Borrowings	29,855
Secured Convertible Debentures
Disclosure Of Detailed Information About Borrowings [Line Items]
Borrowings	$ 2,600

Long-term Debt - Summary of C_2

Long-term Debt - Summary of Carrying Value of Long-term Debt (Parenthetical) (Details) $ in Thousands	6 Months Ended
	Jun. 30, 2021CAD ($)
First Term Loan
Disclosure Of Detailed Information About Borrowings [Line Items]
Principal/face amount	$ 10,000
Maturity date	April 23, 2024
First Term Loan | Fixed Interest Rate
Disclosure Of Detailed Information About Borrowings [Line Items]
Interest rate	8.00%
First Term Loan | Effective Interest Rate
Disclosure Of Detailed Information About Borrowings [Line Items]
Interest rate	15.05%
Second Term Loan
Disclosure Of Detailed Information About Borrowings [Line Items]
Principal/face amount	$ 29,123
Maturity date	April 23, 2024
Second Term Loan | Fixed Interest Rate
Disclosure Of Detailed Information About Borrowings [Line Items]
Interest rate	10.00%
Second Term Loan | Effective Interest Rate
Disclosure Of Detailed Information About Borrowings [Line Items]
Interest rate	10.47%
Secured Convertible Debentures
Disclosure Of Detailed Information About Borrowings [Line Items]
Principal/face amount	$ 2,410
Maturity date	March 31, 2022
Secured Convertible Debentures | Fixed Interest Rate
Disclosure Of Detailed Information About Borrowings [Line Items]
Interest rate	8.00%
Secured Convertible Debentures | Effective Interest Rate
Disclosure Of Detailed Information About Borrowings [Line Items]
Interest rate	8.24%

Share Capital and Other Equit_3

Share Capital and Other Equity Instruments - Schedule of Changes in Issued and Outstanding Common Shares (Details) - CAD ($) $ in Thousands	Jan. 29, 2020	Jun. 30, 2021	Jun. 30, 2020
Disclosure Of Classes Of Share Capital [Abstract]
Balance - beginning of period, Number		29,943,839	23,313,164
Issued to acquire assets, Number	96,833	0	96,833
Shares issued pursuant to a restricted share units plan, Number		0	10,355
Balance - end of period, Number		29,943,839	23,420,352
Balance - beginning of period		$ 977,261	$ 932,951
Issued to acquire assets		0	1,240
Shares issued pursuant to a restricted share units plan		0	9,764
Balance - end of period		$ 977,261	$ 943,955

Share Capital and Other Equit_4

Share Capital and Other Equity Instruments - Share Capital - Additional Information (Details) - CAD ($) $ in Thousands	Jan. 29, 2020	Jun. 30, 2021	Mar. 31, 2021	Jun. 30, 2020
Disclosure Of Classes Of Share Capital [Abstract]
Shares issued in settlement of license acquisition payment obligation	96,833	0		96,833
Carrying value liabilities	$ 1,319
Shares issued in payment to suppliers	$ 1,240
Gain (loss) on extinguishment of liabilities			$ 79

Share Capital and Other Equit_5

Share Capital and Other Equity Instruments - Schedule of Changes in Number of Stock Options Outstanding and Weighted Average Exercise Price (Details)	May 26, 2020$ / shares	Jun. 30, 2021shares$ / shares	Jun. 30, 2021shares$ / shares	Jan. 31, 2021shares	Jun. 30, 2021shares$ / shares	Jun. 30, 2021shares$ / shares	Jun. 30, 2020shares$ / shares
Disclosure Of Classes Of Share Capital [Line Items]
Number of Share Options, Beginning Balance | shares					2,485,555	2,485,555	2,209,864
Number of Share Options, Granted | shares		50,000	50,000	40,000			436,570
Number of Share Options, Forfeited | shares					(850,274)	(850,274)	(64,141)
Number of Share Options, Expired | shares							(1,435)
Number of options, Repriced - options before repricing | shares							(1,929,685)
Number of options, Repriced - options after repricing | shares							1,929,685
Number of share Options, Ending Balance | shares		1,635,281	1,635,281		1,635,281	1,635,281	2,580,858
Weighted Average Exercise Price, Beginning Balance | $ / shares					$ 18.70		$ 38.72
Weighted Average Exercise Price, Granted | $ / shares							14.06
Weighted Average Exercise Price, Forfeited | $ / shares					15.11		24.42
Weighted Average Exercise Price, Expired | $ / shares							2,433.20
Weighted Average Exercise Price, Repriced - options before repricing | $ / shares							35.14
Weighted Average Exercise Price, Repriced - options after repricing | $ / shares	$ 15.21						15.21
Weighted Average Exercise Price, Ending Balance | $ / shares		$ 20.56			$ 20.56		$ 18.67
US$
Disclosure Of Classes Of Share Capital [Line Items]
Number of Share Options, Beginning Balance | shares					305,000	305,000
Number of Share Options, Granted | shares					90,000	90,000
Number of share Options, Ending Balance | shares		395,000	395,000		395,000	395,000
Weighted Average Exercise Price, Beginning Balance | $ / shares						$ 4.70
Weighted Average Exercise Price, Granted | $ / shares						4.65
Weighted Average Exercise Price, Ending Balance | $ / shares			$ 4.69			$ 4.69

Share Capital and Other Equit_6

Share Capital and Other Equity Instruments - Contributed Surplus (Share-Based Payments) - Additional Information (Details)	Jun. 08, 2020shares$ / shares	May 26, 2020CAD ($)$ / shares	Jun. 30, 2021shares$ / shares	Jan. 31, 2021shares$ / shares	Jun. 30, 2021CAD ($)	Mar. 31, 2021CAD ($)shares	Jun. 30, 2020CAD ($)shares$ / shares	Jun. 30, 2021CAD ($)shares	Jun. 30, 2020CAD ($)shares
Disclosure Of Classes Of Share Capital [Line Items]
Number of Share Options, Granted | shares			50,000	40,000			436,570
Exercise price of options granted | $ / shares			$ 4.09	$ 5.34
Number of stock options vested | shares			25,000	20,000
Vesting period			1 year	1 year
Weighted Average Exercise Price, Repriced - options after repricing | $ / shares		$ 15.21					$ 15.21
Incremental fair value of the repricing options		$ 3,000,000
Share-based payment compensation expense					$ 957,000		$ 2,424,000	$ 1,866,000	$ 4,801,000
Share-based payments expense (note 11b)								1,845,000	4,761,000
Stock Options
Disclosure Of Classes Of Share Capital [Line Items]
Weighted average exercise price of repricing options | $ / shares	$ 27	$ 15.21
Weighted Average Exercise Price, Repriced - options after repricing | $ / shares	$ 36	$ 15.21
Number of repricing of options outstanding | shares	1,929,685
Share-based payment compensation expense					957,000		2,407,000	1,866,000	$ 4,770,000
Restricted Share Units
Disclosure Of Classes Of Share Capital [Line Items]
Share-based payment compensation expense					$ 0			$ 0
Number RSU paid in cash | shares						2,948		144	2,948
Reduction to contributed surplus						$ 40,000
Share-based payments
Disclosure Of Classes Of Share Capital [Line Items]
Share-based payments expense (note 11b)							$ 17,000		$ 31,000

Share Capital and Other Equit_7

Share Capital and Other Equity Instruments - Summary of Weighted Average Inputs into Model and Resulting Grant Date Fair Values (Details)	May 26, 2020yr$ / shares	Jun. 30, 2021yr$ / shares
Disclosure Of Classes Of Share Capital [Abstract]
Expected volatility of share price	93.20%	115.50%
Risk-free interest rate	0.40%	0.99%
Expected life in years | yr	6.3	6.5
Weighted average grant date fair value | $ / shares	$ 1.55	$ 5

Share Capital and Other Equit_8

Share Capital and Other Equity Instruments - Schedule of Stock Options Issued and Outstanding by Range of Exercise Price (Details)	6 Months Ended
	Jun. 30, 2021shares$ / shares	Jun. 30, 2021shares$ / shares	Mar. 31, 2021shares$ / shares	Mar. 31, 2021shares$ / shares	Jun. 30, 2020shares$ / shares	Mar. 31, 2020shares$ / shares
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Number outstanding, options | shares	1,635,281	1,635,281	2,485,555	2,485,555	2,580,858	2,209,864
Weighted average remaining contractual life (in years)	8 years 2 months 12 days
Options outstanding, weighted average exercise price | $ / shares	$ 20.56		$ 18.70		$ 18.67	$ 38.72
Number exercisable, options | shares	818,188	818,188
Options exercisable, weighted average exercise price | $ / shares	$ 26.61
US$
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Number outstanding, options | shares	395,000	395,000	305,000	305,000
Weighted average remaining contractual life (in years)	9 years 6 months
Options outstanding, weighted average exercise price | $ / shares		$ 4.69		$ 4.70
Number exercisable, options | shares	168,333	168,333
Options exercisable, weighted average exercise price | $ / shares		$ 4.50
$7.86 - $11.99
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Number outstanding, options | shares	171,250	171,250
Weighted average remaining contractual life (in years)	8 years 3 months 18 days
Options outstanding, weighted average exercise price | $ / shares	$ 9.58
Number exercisable, options | shares	68,672	68,672
Options exercisable, weighted average exercise price | $ / shares	$ 9.73
$14.06
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Number outstanding, options | shares	323,926	323,926
Weighted average remaining contractual life (in years)	8 years 10 months 24 days
Options outstanding, weighted average exercise price | $ / shares	$ 14.06
Number exercisable, options | shares	112,972	112,972
Options exercisable, weighted average exercise price | $ / shares	$ 14.06
$15.21
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Number outstanding, options | shares	1,083,328	1,083,328
Weighted average remaining contractual life (in years)	7 years 10 months 24 days
Options outstanding, weighted average exercise price | $ / shares	$ 15.21
Number exercisable, options | shares	580,241	580,241
Options exercisable, weighted average exercise price | $ / shares	$ 15.21
$27.00 - $3,170.00
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Number outstanding, options | shares	56,777	56,777
Weighted average remaining contractual life (in years)	7 years 7 months 6 days
Options outstanding, weighted average exercise price | $ / shares	$ 192.87
Number exercisable, options | shares	56,303	56,303
Options exercisable, weighted average exercise price | $ / shares	$ 189.91
$4.09 - $5.34 | US$
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Number outstanding, options | shares	375,000	375,000
Weighted average remaining contractual life (in years)	9 years 6 months
Options outstanding, weighted average exercise price | $ / shares		$ 4.36
Number exercisable, options | shares	165,000	165,000
Options exercisable, weighted average exercise price | $ / shares		$ 4.37
$10.80 | US$
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Number outstanding, options | shares	20,000	20,000
Weighted average remaining contractual life (in years)	9 years 3 months 18 days
Options outstanding, weighted average exercise price | $ / shares		$ 10.80
Number exercisable, options | shares	3,333	3,333
Options exercisable, weighted average exercise price | $ / shares		$ 10.80

Share Capital and Other Equit_9

Share Capital and Other Equity Instruments - Schedule of Stock Options Issued and Outstanding by Range of Exercise Price (Parenthetical) (Details) - Jun. 30, 2021	$ / shares	$ / shares
$14.06
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Range of exercise price	$ 14.06
$15.21
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Range of exercise price	15.21
$10.80 | US$
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Range of exercise price		$ 10.80
Bottom of Range | $7.86 - $11.99
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Range of exercise price	7.86
Bottom of Range | $27.00 - $3,170.00
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Range of exercise price	27
Bottom of Range | $4.09 - $5.34 | US$
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Range of exercise price		4.09
Top of Range | $7.86 - $11.99
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Range of exercise price	11.99
Top of Range | $27.00 - $3,170.00
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Range of exercise price	$ 3,170
Top of Range | $4.09 - $5.34 | US$
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Range of exercise price		$ 5.34

Share Capital and Other Equi_10

Share Capital and Other Equity Instruments - Schedule of Changes in Number of RSU outstanding (Details) - Restricted Share Units	3 Months Ended	6 Months Ended
	Mar. 31, 2021shares	Jun. 30, 2021shares	Jun. 30, 2020shares
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Balance - beginning of period	4,216	4,216	17,565
Forfeited		(4,048)	(24)
Released			(10,355)
Paid in cash	(2,948)	(144)	(2,948)
Balance - end of period		24	4,238

Share Capital and Other Equi_11

Share Capital and Other Equity Instruments - Schedule of Total Share-Based Payments Expense (Details) - CAD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Share-based payments expense	$ 957	$ 2,424	$ 1,866	$ 4,801
Loss from Discontinued Operations
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Share-based payments expense	(409)	180	(444)	185
Research and Development Expenses
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Share-based payments expense	467	904	437	1,920
Administration, Selling and Marketing Expenses
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Share-based payments expense	$ 899	$ 1,340	$ 1,873	$ 2,696

Share Capital and Other Equi_12

Share Capital and Other Equity Instruments - Summary of Changes in Number of Warrants Outstanding and Weighted Average Exercise Price (Details)	Jun. 30, 2021Warrant$ / shares	Jun. 30, 2021Warrant$ / shares	Jun. 30, 2020Warrant$ / shares
Disclosure Of Classes Of Share Capital [Line Items]
Number of warrants, end of period | Warrant	172,735	172,735	172,735
Weighted average exercise price, end of period | $ / shares	$ 84.33		$ 84.33
US$
Disclosure Of Classes Of Share Capital [Line Items]
Number of warrants, end of period | Warrant	7,894,734	7,894,734
Weighted average exercise price, end of period | $ / shares		$ 5.50

Share Capital and Other Equi_13

Share Capital and Other Equity Instruments - Warrants - Additional Information (Details) - shares	Nov. 25, 2020	Jun. 30, 2021
Disclosure Of Classes Of Share Capital [Abstract]
Number of warrants issued	7,894,734	0

Share Capital and Other Equi_14

Share Capital and Other Equity Instruments - Schedule of Warrants Outstanding, Exercise Price, Expiry Rate and Overall Weighted Average Exercise Price (Details)	6 Months Ended
	Jun. 30, 2021Warrant$ / shares	Jun. 30, 2021Warrant$ / shares	Jun. 30, 2020Warrant$ / shares
Disclosure Of Classes Of Share Capital [Line Items]
Number | Warrant	172,735	172,735	172,735
Exercise price (CA$) | $ / shares	$ 84.33		$ 84.33
Warrant Expires on January 2023
Disclosure Of Classes Of Share Capital [Line Items]
Number | Warrant	4,000	4,000
Expiry date	Jan. 31, 2023
Exercise price (CA$) | $ / shares	$ 3,000
Warrant Expires on April 2027
Disclosure Of Classes Of Share Capital [Line Items]
Number | Warrant	168,735	168,735
Expiry date	Apr. 30, 2027
Exercise price (CA$) | $ / shares	$ 15.21
Warrant Expires on November 2025
Disclosure Of Classes Of Share Capital [Line Items]
Number | Warrant	7,894,734	7,894,734
Expiry date	Nov. 30, 2025
Exercise price (CA$) | $ / shares		$ 5.50

Government Grants - Summary of

Government Grants - Summary of Government Grants (Details) - CAD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Disclosure Of Government Grants [Line Items]
Government grants recognized	$ 1,204	$ 2,945	$ 4,105	$ 2,945
Research and Development Expenses
Disclosure Of Government Grants [Line Items]
Government grants recognized	149	460	512	460
Administration Expenses
Disclosure Of Government Grants [Line Items]
Government grants recognized	115	584	411	584
Loss from Discontinued Operations
Disclosure Of Government Grants [Line Items]
Government grants recognized	$ 940	$ 1,901	$ 3,182	$ 1,901

Related Party Transactions - Ad

Related Party Transactions - Additional Information (Details) - CAD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Related Party Transactions [Line Items]
Interest paid on loan			$ 973	$ 503
SALP
Related Party Transactions [Line Items]
Interest expense	$ 1,054	$ 311	2,091	619
Interest paid on loan		$ 252	973	$ 503
Legal expenses	$ 145		$ 145

Subsequent Events - Additional

Subsequent Events - Additional Information (Details) - USD ($) $ in Millions	Jul. 09, 2021	Jun. 04, 2021
Kedrion S.p.A
Disclosure Of Nonadjusting Events After Reporting Period [Line Items]
Upfront payment received		$ 105
Upfront payment received, net of selling costs		$ 103.5
Discontinued Operations | Definitive Agreement for Sale | PRV
Disclosure Of Nonadjusting Events After Reporting Period [Line Items]
Percentage of net proceeds from subsidiaries		30.00%
Discontinued Operations | Plasma Collection Entities | Kedrion S.p.A
Disclosure Of Nonadjusting Events After Reporting Period [Line Items]
Purchase price received	$ 9.1